New study tests Twice-Daily radiation to boost T-Cell attack on lymphoma
NCT ID NCT06898905
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 34 times
Summary
This study tests a new way to give radiation before T-cell therapies (CAR T or bispecific antibodies) for people with relapsed or refractory diffuse large B-cell lymphoma. Each participant's tumor is split in half: one side gets once-daily radiation, the other gets twice-daily radiation. The goal is to see if twice-daily dosing is safer and more practical. Only 10 adults with large tumors (5 cm or bigger) will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy
What this could lead to
If successful, this could identify a better radiation schedule to help T-cell therapies work more effectively against large lymphoma tumors.
What could go wrong
This is a very small early feasibility study with only 10 participants, so results may not apply broadly. The main goal is safety and practicality, not yet proving which schedule is better.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.